Corcept revives its Cushing’s bid with relacorilant, yet the hardest evidence gap remains
Read how Corcept’s relacorilant NDA resubmission could reshape Cushing’s treatment while efficacy and liver safety questions remain.
Pharma & Biotech
Pharma & Biotech
Corcept’s relacorilant CRL leaves endocrinology ambitions in limbo as oncology pivot takes center stage
Find out why FDA’s complete response letter for Corcept’s relacorilant could reshape treatment of hypercortisolism, with implications for oncology approval.
Medical Devices & Diagnostics
Can Roivios’ JuxtaFlow device redefine kidney support in heart failure and cardiac surgery patients?
Roivios Ltd., a clinical-stage medical device developer, has announced encouraging results from its first-in-human study of the JuxtaFlow Renal Assist Device, a technology designed to support fluid removal and renal function in patients with diuretic-resistant cardiorenal syndrome and acute decompensated heart failure. The results, published in the ASAIO Journal, showed that JuxtaFlow significantly improved both